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Abstract
Objective and design Several works in the setting of early
experimental diabetic nephropathy using anti-inflammatory
drugs, such as the calcineurin inhibitor FK506, have shown
prevention of the development or amelioration of renal
injury including proteinuria. The exact mechanisms by
which anti-inflammatory drugs lower the albuminuria have
not been still clarified well.
Materials The diabetic rats were induced by using
streptozotocin.
Treatment The diabetic rats were subjected to oral FK506
treatment at a dose of 0.5 or 1.0 mg/kg daily for 4 weeks.
Methods Renal histology for the ultrastructural evalua-
tion was determined by electron microscope, followed by
analyses of renal nephrin and podocin and detection of
renal iNOS? macrophages and NF-jB-p-p65?.
Results Elevated 24-h urinary albumin excretion rate was
markedly attenuated by FK506 treatment. In diabetic
model rats, FK506 treatment at a dose of 0.5 or 1.0 mg/kg
significantly increased the expression of nephrin and
podocin when compared to control. As expected, rats in
control diabetic group had an increase in GBM thickening
and foot process effacement when compared to normal
rats; increased GBM thickening and foot process efface-
ment were ameliorated by FK506 treatment with 0.5 and
1.0 mg/kg. Histologically, there was marked accumulation
of ED-1?cells (macrophages) in diabetic kidneys, and
FK506 treatment failed to inhibit it. In contrast, FK506
treatment at 0.5 and 1.0 mg/kg doses significantly inhibited
the elevated ED-1?/iNOS? cells in the kidneys of diabetic
rats. ED-1?/NF-jB-p-p65? cells were significantly
increased in positive diabetic kidneys compared to those of
normal rats. FK506 treatment at 0.5 and 1.0 mg/kg sig-
nificantly attenuated the elevated ED-1?/NF-jB-p-p65?
cells in diabetic kidneys. Additionally, a positive correla-
tion was observed between ED-1?/iNOS? cells and
albuminuria (r = 0.87, p\ 0.05). Likewise, ED-1?/
iNOS? cells were correlated negatively with both nephrin
and podocin protein (r = -0.70, p\ 0.05; r = -0.68,
p\ 0.05, respectively).
Conclusion Our results show that FK506 not only upreg-
ulates expression of nephrin and podocin but also inhibits
macrophage activation to protect against podocyte injury.
Keywords Diabetic nephropathy  FK506  Podocytes 
Nephrin  Podocin  Macrophage
Introduction
Diabetic nephropathy (DN), one of the major serious com-
plications of diabetes mellitus, is the leading cause of end-
stage renal disease and highmortality in diabetic patients [1].
The appearance of microalbuminuria is a detectable early
marker of DN [2]. Microalbuminuria may develop into
severe proteinuria and progressively decline glomerular fil-
tration rate (GFR) [3]. The detailed molecular mechanisms
underlying the correlation between albuminuria and DN
remain elusive. The pathogenesis of DN involves numerous
factors, such as hyperglycemia, advanced glycation end
products, poly(ADP-ribose) polymerase activation, protein
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kinase C, oxidative stress and inflammation [4–6]. Chronic
inflammation is closely associated with permeability chan-
ges in the glomerular filtration barrier and proteinuria in DN
[7]. Podocytes are located at the outer layer of the filtration
barrier, and injury to podocytes is involved in the inflam-
matory processes of DN [8]. Recently, several experimental
reports showed the presence of altered nephrin and podocin
expression in different models of diabetic nephropathy, such
asmicewith streptozotocin (STZ)-induced diabetes and non-
obese diabetic mice [9, 10]. Previous study demonstrated
that activated macrophages produce proinflammatory
cytokines and thereby repress expression of nephrin in
podocytes, leading to development of proteinuria, which
revealed that activatedmacrophages play a crucial role in the
injury of podocytes [11].
Emerging evidence suggests inflammation to play
essential roles in the pathogenesis of diabetic complica-
tions including DN, and macrophages show a central role
in the process. Infiltrating macrophages have been found in
both diabetic kidneys from experimental animal models
and human DN renal biopsies. However, mounting results
tend to indicate that it is the activation state of recruited
macrophages, rather than their infiltrating numbers, that
finally determines the evolvement and prognosis of renal
injury [12]. Direct evidence that macrophages can induce
proteinuria comes from adoptive transfer studies in
experimental glomerulonephritis [13]. In this model, mac-
rophage-induced proteinuria is dependent upon the state of
macrophage activation, with interferon-c (IFN-c) activa-
tion of macrophages augmenting proteinuria, while
glucocorticoids suppress the macrophage pro-inflammatory
response and inhibit proteinuria [14].
FK506 is a novel potent immunosuppressant alike
cyclosporin A (CsA) and was able to prevent early DN
progression through the anti-inflammatory effects [15]. In a
previous study, we showed that FK506 beneficially affected
the progression of DN, reducing albuminuria in diabetes is
associated with inhibit early kidney hypertrophy and ECM
expansion in STZ-induced diabetic rats [16]. However, the
exact mechanisms by which calcineurin inhibitors lower the
albuminuria have not been still clarified well. Therefore, the
aim of this study was to test the hypothesis that FK506
attenuates albuminuria through protection against podocyte
impairment via regulation of activated macrophages in
early experimental diabetic kidney.
Materials and methods
Drugs and reagents
FK506 was purchased from Fujisawa Pharmaceutical Co.,
Ltd (Osaka, Japan), STZ was purchased from Sigma
Chemical Co (St. Louis, Mo, USA), microalbumin assay
kit was purchased from Exocell Inc (Philadelphia, Pa.,
USA), and blood glucose assay kits were purchased from
the Nanjing Jiancheng Bioengineering Institute (Nanjing,
China). Anti-CaN, nephrin, podocin, phosphorylated NF-
jB p65 (p-p65) and iNOS polyclonal antibody were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Mouse anti-macrophage monoclonal (ED-1) anti-
body was from Boster Biotechnology (Wuhan, China).
Horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG as well as fluorescein isothiocyanate (FITC)-conju-
gated goat anti-rabbit IgG was from Boster Biotechnology
(Wuhan, China). Chemiluminescence kit was from Amer-
sham Life Science (Little Chalfont, UK).
Animals
Male Munich-Wistar rats (weight 180–200 g) were
obtained from the Experimental Animal Center of Anhui
Medical University. A research protocol in accordance
with the principles was approved by the animal ethics
committee of Anhui Medical University. Animals were
housed in wire-bottomed cage under a 12-h light/dark
cycle. Room temperature (about 24 ± 1 C) and humidity
(about 60 %) were controlled automatically. The rats were
allowed free access to standard laboratory chow and tap
water.
Experimental design
After several days of adaptation, the rats were intraperi-
toneally injected with STZ diluted in citrate buffer 0.1 M
(pH 4.0) at a dose of 65 mg/kg following overnight fasting.
Two days later, the diabetic state was confirmed by mea-
surement of tail blood glucose levels using a reflectance
meter (one touch II, Lifescan LTD, China). Blood glucose
levels were measured twice a week. Diabetic rats were then
divided into three groups (n = 10 per group), avoiding any
inter-group differences in blood glucose levels. A control
group of rats was also included. The normal and control
diabetic group was given 0.5 % sodium carboxymethyl-
cellulose (CMC-Na), while the experiments rats were given
orally the FK506 (suspended in 0.5 % CMC-Na) at a dose
of 0.5 and 1.0 mg/kg daily using a stomach tube for
4 weeks.
Blood sample and tissue collection
After treated for 4 weeks, body weight of the rats was
measured at the end of the experiment. Rats were then
anesthetized by intraperitoneal injection of sodium pento-
barbital (50 mg/kg) and placed on a temperature-regulated
table. The right jugular artery was catheterized and used for
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blood sampling. Blood glucose levels were determined
with a glucose analyzer. The kidney was perfused in vivo
via the abdominal aorta with 100 ml of normal saline at
4 C. The left renal vein was punctured to permit the
perfusate to drain, and the kidney was removed immedi-
ately and snap-frozen in isopentane (-70 C) for
subsequent histologic studies. The remaining kidney was
stored at -70 C for Western blotting analysis.
Urinary albumin excretion
Prior to killing, rats were placed in metabolic cages for
collection of urine over 24-h period of time and used for
measurement of albumin levels. After centrifugation, ali-
quots of the supernatant from urine sample were frozen at
-70 C for subsequent analysis of albumin levels by using
an enzyme-linked immunoabsorbent assay with an anti-rat
albumin antibody. The 24-h albumin excretion was calcu-
lated by multiplying the urinary albumin excretion by the
24-h urine volume.
Renal histology
For the ultrastructural evaluation, the kidney tissue was
fixed in 3 % glutaraldehyde, postfixed in 1 % osmium
tetroxide, imbued with uranyl acetate and embedded in
epoxy resin (epon). The specimen was thin sectioned and
examined under a transmission electron microscope (JEM-
1200EX II; JEOL, Tokyo, Japan).
Electron micrographs of 5–10 glomeruli per kidney
were randomly taken at magnification 10009 and 20,0009
for each rat. The mean glomerular basement membrane
(GBM) thickness was calculated using the measurements
from three different sites in the cross section, with the aid
of Image J. Tangentially sectioned GBM was excluded
from the analysis. Photomicrographs of the GBM were also
analyzed for the density of slit pores between the podocyte
foot processes using published methods [17]. The number
of slit pores was counted and divided by the GBM length
(mm) to arrive at the linear density.
Protein extraction and Western blot
Kidney tissue samples were homogenized and lysed in an
SDS-PAGE sample buffer, boiled and centrifuged, and the
supernatant was recovered by centrifuge. The protein
concentration was quantified by using a dye binding assay
of Bradford, with bovine serum albumin as a standard.
Protein samples were then separated by SDS-PAGE,
electroblotted onto nitrocellulose membranes, incubated
with a blocking buffer for 1 h and then incubated with
primary antibody overnight at 4 C. The membranes were
then incubated with a HRP-labeled goat anti-rabbit IgG.
The bound secondary antibody was detected by enhanced
chemiluminescence. Housekeeping protein b-actin was
used as a loading control. Positive immunoreactive bands
were quantified densitometrically (Leica Q500IW image
analysis system) and expressed as ratio of CaN, nephrin
and podocin to b-actin in optical density units.
Immunohistochemistry
Immunofluorescence analysis of nephrin and podocin in the
renal tissue was performed on 4-lm cryostat sections.
Sections were fixed in acetone/ethanol (4:1) solution for
10 min and washed in phosphate-buffered saline (PBS).
The samples were incubated with 10 % normal goat serum
in PBS at room temperature for 1 h and after that with
either anti-nephrin antibody or antibody to podocin in 1 %
normal goat serum in PBS for 2 h at room temperature.
The slides were washed with PBS, and the primary anti-
body was incubated with FITC-conjugated goat anti-rabbit
IgG diluted in 1 % normal goat serum in PBS for 1 h at
room temperature. Nephrin and podocin immunoreactivi-
ties were analyzed by measuring fluorescence intensity by
digital image analysis of images obtained by using a low-
light video camera (Beijing Aeronautic and Aerospace
University, Beijing, China).
Immunoperoxidase staining for ED-1? macrophages
was conducted on 2-lm sections of formalin-fixed renal
tissue using antigen retrieval (microwave oven heating in
0.1 M sodium citrate pH 6.0 for 10 min) followed by a
three-layer streptavidin–biotin peroxidase complex stain-
ing method. Quantitative analysis of ED-1? macrophages
in the glomeruli was performed under 4009 magnifica-
tion and expressed as cells/glomerular cross section
(gcs). For each section, 20 sequential glomerular profiles
were examined. All scoring was performed on blinded
slides.
Double immunohistochemical staining to simultaneous
detection of iNOS? macrophages and NF-jB-p-p65?
macrophages was also performed on formalin-fixed paraf-
fin sections (2 lm thick). Immunoperoxidase staining of
ED-1 was performed as described above. After develop-
ment with DAB, the sections were placed in 500 ml of
0.1 M sodium citrate buffer (pH 6.0) and microwave-
treated for 10 min and then incubated sequentially with
10 % normal goat serum for 10 min followed by anti-iNOS
antibody (1:100) and anti-NF-jB-p-p65 antibody (1:100)
overnight at 4 C. The sections were subsequently incu-
bated with alkaline phosphatase-labeled goat anti-rabbit
IgG antibody and developed with AP-Red to produce a red
color. The method for calculating positive double-stained
cells is described above.
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Statistical analysis
Data were expressed as the mean ± SEM unless otherwise
specified. One-way analysis of variance with pairwise
comparisons according to the Tukey method was per-
formed. Since urinary albumin excretion rate followed a
non-normal distribution, log transformation analysis was
performed prior to statistical analysis of this parameter.
Differences were considered significant if the P value was
less than 0.05. Correlation analysis was calculated using
the Spearman rank-order correlation, and the p value\0.05
was considered to be statistically significant.
Results
The effects of FK506 on the clinical characteristics
of the diabetic rats
The positive control diabetic rats showed to have increased
blood glucose levels. However, there were no effects on
blood glucose observed in FK506-treated rats. The ratio of
kidney weight to body weight (relative kidney weight) was
significantly higher in control diabetic than that in normal
rats. FK506 treatment with 1.0 mg/kg for 4 weeks signifi-
cantly reduced relative kidney weight in diabetic rats. In
positive control diabetic rats, albuminuria was significantly
increased when compared to normal rats, whereas FK506
treatment at 0.5 and 1.0 mg/kg markedly attenuated the
increase in albuminuria from the diabetic rats, although the
level was still higher than that of rats (Table 1).
FK506 recovers GBM thickening and podocyte foot
process in diabetes kidney
The kidney ultrastructure was further examined by electron
microscopy. As shown in Fig. 1 and Table 2, normal
morphology of the glomerular filtration barrier including
GBM and podocyte foot process was seen in normal rats.
As expected, rats in control diabetic group had an increase
in GBM thickening and foot process effacement when
compared to normal rats, increased GBM thickening and
foot process effacement were ameliorated by FK506
treatment with 0.5 and 1.0 mg/kg.
FK506 inhibits CaN expression in diabetic kidney
To detect molecular changes in these experimental rats, we
performed Western blot analysis of renal CaN expression
(Fig. 2). The data showed an increase in amount of
immunoreactive peptide in the kidney of positive control
diabetic rats compared to that of normal rats. Specifically,
densitometric analysis of the Western blot showed a 2.4-
fold increase in the amount of CaN in positive control
diabetic rats compared to the normal rats. In contrast,
FK506 treatment at 0.5 and 1.0 mg/kg reduced levels of
CaN protein by 38.0 and 73.2 %, respectively.
FK506 recovers nephrin expression in diabetic
kidney
To further reveal the mechanism responsible for the pre-
vention in albuminuria in FK506-treated diabetic rats, we
studied the expression of nephrin, a key protein of the
glomerular slit membrane. We first assessed the expression
of nephrin by immunohistochemistry. As shown in Fig. 3,
there was a finely dotted linear epithelial staining in the
normal group glomeruli. In contrast, the staining of glo-
meruli from untreated diabetic rats was attenuated, more
dispersed and clustered. Importantly, this diabetic-induced
loss of glomerular nephrin expression was to a large degree
prevented by FK506 treatment with 0.5 and 1.0 mg/kg.
As we observed a prevention of the diabetic-induced
nephrin loss by FK506, we next measured the nephrin
expression by Western blotting analysis to confirm and
quantitatively analyze the results obtained from the
immunohistological evaluation. The results are shown in
Fig. 4; nephrin was expressed as a single band. Hyper-
glycemia of 4 weeks reduced the expression of nephrin
significantly as observed with immunohistochemical
Table 1 Clinical and biochemical parameters in four groups of rats
Group Glu (mmol L-1) BW (g) KW/BW (g/100 g) UAERa (mg24 h-1)
Normal 6.88 ± 0.81 351.6 ± 15.40 0.30 ± 0.04 0.299/71.1
Control diabetic 26.80 ± 2.98** 224.2 ± 13.20** 0.51 ± 0.04* 0.959/71.2**
Control diabetic ? FK506 0.5 mg/kg 27.10 ± 2.44** 227.8 ± 12.64** 0.46 ± 0.05* 0.789/71.1*,#
Control diabetic ? FK506 1.0 mg/kg 27.22 ± 2.35** 258.2 ± 18.87** 0. 34 ± 0.06# 0.559/71.1**,##
Data are expressed as mean ± SEM. Number of rats in each group was 10. A shown as geometric mean tolerance factor
Glu glucose, BW body weight, KW/BW kidney-to-body weight ratio, UAER urinary albumin excretion rate
* p\ 0.05 compared with normal group; ** p\ 0.01 compared with normal group; # p\ 0.05 compared with control diabetic group;
## p\ 0.01 compared with control diabetic group
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analysis. Diabetic-induced nephrin loss is again prevented
in FK506-treated rats.
FK506 recovers podocin expression in diabetic
kidney
To explore the role of other slit diaphragm proteins, we
secondly performed tissue analysis of other slit diaphragm
proteins, podocin. The staining of podocin was revealed to
form a linear pattern along the glomerular capillary wall in
the normal group glomeruli. Notably, the glomerular
expression of podocin was significantly reduced in the dia-
betic rats and was barely detectable, treatment with FK506
moderately but significantly reduced the disappearance of
podocin from the glomeruli of diabetic rats (Fig. 5).
As we observed a prevention of the diabetic-induced
podocin loss by FK506, we next measured the podocin
expression by Western blotting analysis to confirm and
quantitatively analyze the results obtained from the
immunohistological tissue evaluation. Western blotting
analysis of podocin is shown in Fig. 6. Diabetic-induced
podocin loss is also prevented by FK506 treatment with 0.5
and 1.0 mg/kg.
FK506 inhibits macrophage activation in diabetic
kidney
To assess the potential effect of FK506 on renal inflam-
mation, we examined renal infiltration of the ED-1 positive
macrophages in STZ-induced DN rats. As shown in Fig. 7,
compared with control rats, DN rats exhibited significant
macrophages infiltration in the glomeruli at week 4 after
STZ induction. However, FK506-treated rats did not show
reduction in macrophage infiltrations. In addition, ED-1?/
Fig. 1 Representative micrographs of kidney tissue-stained electron micrograph of a glomerulus from normal rats (a), control diabetic (b),
control diabetic ? FK506 0.5 mg/kg (c) and diabetic ? FK506 1.0 mg/kg (d). Magnification 95000
Table 2 Glomerular ultrastructure parameters in four groups of rats
Group Foot process width (lm) Foot process fusion rate (%) GBM thickness (lm)
Normal 0.27 ± 0.03 2.12 ± 0.36 0.26 ± 0.03
Control diabetic 0.77 ± 0.03* 75.33 ± 14.61* 0.71 ± 0.06*
Control diabetic ? FK506 0.5 mg/kg 0.43 ± 0.02*,# 35.24 ± 6.07*,# 0.42 ± 0.03*,#
Control diabetic ? FK506 1.0 mg/kg 0.41 ± 0.02*,# 33.39 ± 7.48*,# 0.40 ± 0.01*,#
* p\ 0.05 compared with normal group; # p\ 0.05 compared with control diabetic group
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iNOS? cells were also significantly increased in the kid-
neys from positive control diabetic rats but were
significantly suppressed by FK506 treatment (Fig. 8;
Table 3).
FK506 inhibits NF-jB-p-p651 macrophages
in diabetic kidney
ED-1?/NF-jB-p-p65? cells were significantly increased in
positive diabetic kidneys compared to those of normal rats.
Fig. 2 Western blot analysis of calcineurin protein (upper panel) and
densitometric analysis (lower panel) in renal tissue from normal,
control diabetic, diabetic ? FK506 0.5 mg/kg and diabetic ? FK506
1.0 mg/kg. Values are the mean ± SEM. n = 10, **p\ 0.01 versus
C, #p\ 0.05, ##p\ 0.01 versus DM
Fig. 3 Immunofluorescence staining for nephrin. The representative fields show glomerular expression of nephrin as indicated from normal rats
(a), control diabetic (b), control diabetic ? FK506 0.5 mg/kg (c) and diabetic ? FK506 1.0 mg/kg (d). Magnification 9400
Fig. 4 Western blot analysis of nephrin protein (upper panel) and
densitometric analysis (lower panel) in renal tissue from normal,
control diabetic, diabetic ? FK506 0.5 mg/kg and diabetic ? FK506
1.0 mg/kg. Values are the means ± SEM. n = 10, **p\ 0.01 vs C,
#p\ 0.05, ##p\ 0.01 vs DM
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FK506 treatment at 0.5 and 1.0 mg/kg significantly atten-
uated the elevated ED-1?/NF-jB-p-p65? cells in diabetic
kidneys (Fig. 9; Table 3).
Correlation between activated macrophages
and albuminuria, nephrin and podocin protein
As shown in Fig. 10, we found the highest correlation
between ED-1?/iNOS? cells with albuminuria (r = 0.87,
p\ 0.05). Likewise, ED-1?/iNOS? cells showed negative
correlations with nephrin and podocin protein (r = -0.70,
p\ 0.05; r = -0.68, p\ 0.05, respectively).
Discussion
DN is one of the most important health problems world-
wide, and this is likely to worsen to critical levels in the
next decades [1]. Recently, increasing evidence has been
obtained demonstrating that podocytes play an important
role in the pathogenesis of proteinuria and progression of
DN [18]. The present study shows that 4 weeks after
Fig. 5 Immunofluorescence staining for podocin. The representative fields show glomerular expression of podocin as indicated from normal rats
(a), control diabetic (b), control diabetic ? FK506 0.5 mg/kg (c) and diabetic ? FK506 1.0 mg/kg (d). Magnification 9400
Fig. 6 Western blot analysis of podocin protein (upper panel) and
densitometric analysis (lower panel) in renal tissue from normal,
control diabetic, diabetic ? FK506 0.5 mg/kg and diabetic ? FK506
1.0 mg/kg. Values are the means ± SEM. n = 10, **p\ 0.01 vs C,
#p\ 0.05, ##p\ 0.01 vs DM
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induction of diabetes, marked albuminuria associated with
reduction in podocyte-specific protein nephrin and podocin
is established. Furthermore, macrophages recruitment and
activation in the glomeruli were increased in diabetic rats.
FK506 treatment showed significantly increased expression
of nephrin and podocin when compared to control. FK506
treatment results in the inhibited macrophages activation.
The glomerular podocyte is known to play a critical role
in kidney structure and urinary filtration. The podocyte foot
process surrounds the outside of the GBM and the gaps
between adjacent podocyte foot processes form slit dia-
phragms (filtration slits). A series of recent studies have
suggested that podocyte injury plays a key role in the
development of DN [19, 20]. Drugs that have beneficial
effects on podocytes can improve our ability to treat DN
[21]. In the present study, its was shown that after treat-
ment with FK506, the foot process effacement and GBM
thickening ameliorated, suggesting the protective effects of
FK506 against podocyte injury.
Finally, we examined the mechanism underlying the
anti-albuminuric effect of FK506 agonist in diabetes.
Podocyte slit diaphragm plays a critical role in the main-
tenance of normal barrier function of glomerular capillary
wall. The dysfunction of podocyte slit diaphragm causes
proteinuria [22]. As two key functional molecules in
podocyte slit diaphragm, nephrin is located at the outer
leaflet of plasma membranes of podocyte slit diaphragm,
while podocin is the interaction with nephrin [23].
Recently, we and other studies demonstrated that the
alteration in nephrin and podocin is involved in the
development of proteinuria in several models of DN [9].
The anti-proteinuric effect of 1, 25-dihydroxyvitamin D3
has been shown to be closely associated with the preser-
vation of nephrin and podocin expression in STZ-induced
DN rats [24]. Therefore, the abnormal expression and
distribution of nephrin and podocin could be a mechanism
and a therapeutic target for proteinuria in DN.
FK506 is mainly used as an immunosuppressant in
allogeneic organ transplants and autoimmune diseases.
Binding of FK506 to its specific intracellular receptor
(FK506 binding protein) inhibits calmodulin activity.
Clinical observations have found that it can also effectively
reduce renal damage and proteinuria in glomerular diseases
such as MCN, FSGS, MsPGN and MPGN [25, 26]. Our
previous studies documented that FK506 ameliorated
albuminuria and inhibit early kidney hypertrophy and ECM
expansion in STZ-induced diabetic rats, which was possi-
bly achieved through the suppression of the expression of
several injurious cytokines in the glomeruli [16]. However,
we still do not fully understand how albuminuria was
reduced by FK506 in this model. To investigate whether
the anti-albuminuria effect of FK506 could be related to the
Fig. 7 Immunostaining of ED-1. The representative fields show renal expression of ED-1 as indicated, in normal rats (a), control diabetic (b),
control diabetic ? FK506 0.5 mg/kg (c) and diabetic ? FK506 1.0 mg/kg (d). Magnification 9400
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improvement in podocyte slit diaphragm function, we
compared the distribution and expression of nephrin and
podocin at protein levels in glomeruli on 4 weeks after
STZ-induced diabetic rats between FK506 and vehicle
groups. In our study, diabetic kidney nephrin and podocin
expression was significantly downregulated compared with
normal rats. Interestingly, the treatment of FK506 not only
decreased albuminuria, but also recovered the distribution
and expression of nephrin and podocin in glomeruli.
Macrophage infiltration is a common feature in both
human and experimental renal diseases [27]. These infil-
trating cells are strongly associated with the severity of
kidney injury and progressive chronic renal failure. In
experimental crescentic glomerulonephritis, inhibition of
macrophages infiltration in glomerular significantly alle-
viated crescent formation and proteinuria [28]. In our
study, STZ-induced DN rats were clearly characterized by
large macrophage infiltration in the glomeruli and inter-
stitium at the early stage after disease induction, which was
followed by the development of podocyte injury and pro-
found albuminuria, suggesting macrophages as a major
constituent of the infiltrated inflammatory cells in DN.
Although commonly recognized for the pathogenic role
of macrophage in renal inflammation and fibrosis, macro-
phages also play a critical role in tissue remodeling and
repair, as well as in immune regulation. However, macro-
phage infiltration into the kidney is not always pathogenic
because only activated macrophages can produce injury
Fig. 8 Double immunostaining of ED-1/iNOS. The representative fields show renal expression of ED-1/iNOS as indicated, in normal rats (a),
control diabetic (b), control diabetic ? FK506 0.5 mg/kg (c) and diabetic ? FK506 1.0 mg/kg (D). Magnification 9400
Table 3 Semiquantitative assessment of ED-1, ED-1?/NF-jB-p-p65? and ED-1?/iNOS? immunohistochemistry staining in the glomeruli from
four groups of rats
Group ED-1 (cells/gcs) ED-1?/NF-jB-p-p65? (cells/gcs) ED-1?/iNOS? (cells/gcs)
Normal 0.93 ± 0.70 0.91 ± 0.52 0.67 ± 0.46
Control diabetic 3.27 ± 1.22** 3.92 ± 1.76* 2.07 ± 0.59*
Control diabetic ? FK506 0.5 mg/kg 2.80 ± 1.26** 1.60 ± 0.93*,## 1.53 ± 0.48**
Control diabetic ? FK506 1.0 mg/kg 2.73 ± 1.33** 1.20 ± 0.63*,## 1.20 ± 0.56**
gcs was indicated glomerular cross-sectional area. Data are expressed as mean ± SEM. Number of rats in each group was 10
* p\ 0.05 compared with normal group; ** p\ 0.01 compared with normal group; ## p\ 0.01 compared with control diabetic group
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[29]. Recently, using conditionally immortalized reporter
podocytes, Takno et al. [30] found that bystander macro-
phages as well as macrophage-derived cytokines IL-1b and
TNF-a markedly suppressed activity of the nephrin gene
promoter in podocytes. The cytokine-initiated repression
was reversible, observed on both basal and inducible
expression, independent of Wilms’ tumor suppressor WT1
and caused in part via activation of the phosphatidylinos-
itol-3-kinase/Akt pathway. Activated macrophages
produce inflammatory cytokines abundantly, which is
involved in the development of proteinuria in glomerular
disease [31]. The requirement for macrophage activation to
induce podocyte damage is consistent with experimental
studies in which the ability of adoptively transferred
macrophages to induce renal injury is dependent upon their
activated status. Hanning et al. [32] cocultured podocytes
and bone marrow-derived monocyte/macrophage subsets in
a transwell system. Data show that iNOS? macrophages,
but not iNOS- macrophages, induced podocyte injury. In
additional, studies using RAW 264.7 macrophage cells
have shown that expression of inflammatory factors was
induced by calcineurin-activated processes resulting from
activation of NF-jB and suppressed by the calcineurin
inhibitor FK506 [33]. In this study, we observed a signif-
icant increase in the number of ED-1?/iNOS? cells and
ED-1?/NF-jB-p-p65? cells in the STZ rat model; this was,
however, abrogated by FK506 administration. We were
also able to further confirm the strong positive correlation
between ED-1?/iNOS? cells and albuminuria and ED-1?/
iNOS? cells negative correlations with nephrin and podo-
cin protein. These results indicate that in the STZ model of
rat podocyte injury, nephrin and podocin levels are
reduced, likely contributing to increased ED-1?/iNOS?
cells. Extrapolation of these findings to the in vivo setting
requires caution, but we propose that the major mechanism
Fig. 9 Double immunostaining of ED-1/NF-jB-p-p65. The representative fields show renal expression of ED-1/NF-jB-p-p65 as indicated, in
normal rats (a), control diabetic (b), control diabetic ? FK506 0.5 mg/kg (c) and diabetic ? FK506 1.0 mg/kg (d). Magnification 9400
Fig. 10 Plot of correlation between UAER (urinary albumin excre-
tion rate) and ED-1?/iNOS? macrophage numbers (r = 0.87,
p\ 0.05)
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of calcineurin action is related to the upregulation of the
NF-jB-p-p65 in the activated macrophage.
In conclusion, podocyte slit diaphragm dysfunction,
such as the disordered distribution and downregulation of
nephrin and podocin expression, is critically involved in
the pathogenesis of in STZ-induced DN rats. The restora-
tion of the distribution and expression of nephrin and
podocin by FK506 could be an important mechanism by
which FK506 ameliorates podocyte slit diaphragm dys-
function and macrophages activation. However, the current
study is just a proof-of-principle and more studies are
needed to mechanistically investigate macrophage infil-
tration, activation and functions in DN.
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